Hexarelin

What it is

Hexarelin (examorelin) is a synthetic six-amino-acid growth hormone-releasing peptide (GHRP). It was developed in the late 1980s and early 1990s and was studied in clinical trials for GH deficiency diagnosis and short-term investigation of GH-related conditions. Hexarelin is not FDA-approved for any use in the United States.

In published studies, hexarelin was associated with large GH spikes, along with tachyphylaxis (rapid loss of effect with continued exposure) and the most pronounced cortisol elevation of the major GHRPs. These findings limited its further clinical development.

Mechanism of action

Proposed mechanisms come from laboratory, animal, and early human research. Hexarelin has been reported to act through ghrelin receptor (GHS-R1a) activation:

• GH release — in human studies, hexarelin was associated with among the largest GH increases measured for any GHRP
• Cortisol elevation — reported to be greater than with other GHRPs at comparable GH-releasing doses
• Prolactin elevation — reported in research settings
• Tachyphylaxis — receptor desensitization with repeated exposure was reported to diminish the GH response
• Possible direct cardiovascular effects — laboratory and animal research has suggested hexarelin binds receptors in cardiac tissue independent of GH, with implications that are not well understood

Clinical evidence

Hexarelin has been studied in research settings and in small, early-phase clinical trials that characterized its pharmacology. Development for chronic use did not proceed, in part because of the reported tachyphylaxis and cortisol findings. Well-controlled human trials establishing effectiveness and safety are lacking.

Why we don’t prescribe it at The Tide

The Tide does not prescribe hexarelin. Concerns noted in the published literature include:

• Tachyphylaxis: the reported rapid loss of response with repeated exposure
• Cortisol elevation: the largest reported cortisol increase of the major GHRPs
• Cardiovascular effects: reported direct cardiac activity raises unresolved questions, particularly for middle-aged and older adults
• Regulatory status: hexarelin has no FDA approval and no established clinical pathway in the United States

Side effects and contraindications

Human safety has not been established in well-controlled trials, and long-term effects are unknown. Reported concerns include cortisol and prolactin elevation, possible cardiac effects, effects on blood sugar, and growth-promoting signaling in people with malignancy or pituitary disease. Products sold outside regulated channels (e.g., “research peptides”) may vary in purity, dose, and sterility.